The Life Sciences team advised Seagen on its collaboration with Sanofi to design, develop, and commercialize antibody-drug conjugates (ADCs) for up to three cancer targets.
The collaboration will utilize Sanofi’s proprietary monoclonal antibody (mAb) technology and Seagen’s proprietary ADC technology.
Seagen is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people’s lives.
Sanofi is a leading global healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions.
The Goodwin team was led by Adam Bellack, Alan Wang, Chris Zhong (IP), Susan Lee (FDA), and Daniel Karelitz (Tax).